NGR-sIL-24

NGR-sIL-24 is an experimental recombinant fusion protein designed for targeted cancer therapy. It consists of a soluble form of Interleukin-24 (sIL-24), a pro-apoptotic cytokine, fused to an asparagine-glycine-arginine (NGR) motif. The NGR motif acts as a homing peptide that specifically binds to Aminopeptidase N (CD13), which is highly expressed on the surface of various cancer cells and tumor neovasculature. Upon binding and internalization, the sIL-24 moiety induces programmed cell death (apoptosis) through both endoplasmic reticulum (ER) stress-dependent and mitochondria-dependent signaling pathways. This process involves the upregulation of BiP/GRP78, Bax/Bcl-2, and GADD34, leading to cytochrome c release and the activation of caspase-3. Research has demonstrated its efficacy in inhibiting the growth of CD13-positive cancer cell lines, such as U937 (leukemia) and A549 (lung cancer), while sparing normal cells like MRC-5.

Other names

NGR-sIL-24 fusion proteinNGR-sIL24 fusion proteinNGR-sIL 24 fusion proteinNGR-sIL-24 recombinant fusion proteinNGR-sIL24 recombinant fusion proteinNGR-sIL 24 recombinant fusion protein